BP Figure 4: Lack of effect of AZD1656 treatment on blood or liver triglyceride and cholesterol in P446L mice after 20 wk.

Experimental details were as in Figure-1. A) Blood triglycerides and cholesterol after 20 wk on HFHSD showing increased cholesterol (total and LDL) by LL genotype and by AZD1656 treatment in PP but not LL mice. B) Lack of effect of AZD1656 on liver triglyceride and cholesterol and liver enzymes (ALT, alanine aminotransferase; AST, aspartate aminotransferase) in plasma. Decrease in plasma inorganic phosphate by genotype but not by AZD1656. C) Lack of effect of AZD1656 on liver steatosis and fibrosis scores in PP and LL mice. *P < 0.05 effect of AZD1656; #P < 0.05 effect of genotype.